Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Global Blood Ther (NQ: GBT )

40.90 USD +0.09 (+0.22%)
Streaming Delayed Price Updated: 3:29 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 507,038
Open 40.79
Bid (Size) 40.86 (18)
Ask (Size) 40.94 (4)
Prev. Close 40.81
Today's Range 40.50 - 41.17
52wk Range 36.49 - 83.69
Shares Outstanding 62,156,860
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sick
From GlobeNewswire News Releases
GBT Announces New Employment Inducement Grants
From GlobeNewswire News Releases

Performance

YTD
-7.59%
-7.59%
1 Month
-4.82%
-4.82%
3 Month
-19.57%
-19.57%
6 Month
-33.16%
-33.16%
1 Year
-43.96%
-43.96%

More News

Read More
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
From GlobeNewswire News Releases
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
From GlobeNewswire News Releases
GBT Announces New Employment Inducement Grants
From GlobeNewswire News Releases
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
From GlobeNewswire News Releases
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
From GlobeNewswire News Releases
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus
Tags Market News Pre/Market Outlook BRKR
From Benzinga
Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment
Tags GBT News Biotech
From Benzinga
Analysts Anticipate 10% Upside For ESGV
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.